Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension study

  • Takahiko Saida1, 2, 3Email author,
  • Yasuto Itoyama4,
  • Seiji Kikuchi5,
  • Qi Hao1,
  • Takayoshi Kurosawa6,
  • Kengo Ueda6,
  • Lixin Zhang Auberson7,
  • Isao Tsumiyama6,
  • Kazuo Nagato8 and
  • Jun-ichi Kira9
BMC NeurologyBMC series – open, inclusive and trusted201717:17

https://doi.org/10.1186/s12883-017-0794-5

Received: 19 July 2016

Accepted: 11 January 2017

Published: 28 January 2017

Back to article

Open Peer Review reports

Pre-publication versions of this article are available by contacting info@biomedcentral.com.

Original Submission
19 Jul 2016 Submitted Original manuscript
7 Sep 2016 Reviewed Reviewer Report - Espen Benjaminsen
12 Sep 2016 Reviewed Reviewer Report - Kerstin Göbel
26 Oct 2016 Author responded Author comments - Takahiko Saida
Resubmission - Version 2
26 Oct 2016 Submitted Manuscript version 2
17 Nov 2016 Author responded Author comments - Takahiko Saida
Resubmission - Version 3
17 Nov 2016 Submitted Manuscript version 3
12 Dec 2016 Author responded Author comments - Takahiko Saida
Resubmission - Version 4
12 Dec 2016 Submitted Manuscript version 4
Publishing
11 Jan 2017 Editorially accepted
28 Jan 2017 Article published 10.1186/s12883-017-0794-5

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting info@biomedcentral.com.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Institute of Multiple Sclerosis Therapeutics, Kyoto, Japan
(2)
Kyoto Min-Iren-Central Hospital, Kyoto, Japan
(3)
Kyoto University Hospital, Kyoto, Japan
(4)
International University of Health and Welfare, Fukuoka City, Japan
(5)
Hokkaido Medical Center, National Hospital Organization, Sapporo, Japan
(6)
Novartis Pharma KK, Tokyo, Japan
(7)
Novartis Pharma AG, Basel, Switzerland
(8)
Mitsubishi Tanabe Pharma Corporation, Chuo-ku Tokyo, Japan
(9)
Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

Advertisement